查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
软骨发育不全治疗市场：按治疗类型、给药途径、分销管道和地区 - 2023 年至 2030 年的市场规模、份额、前景和机会分析
市场调查报告书
商品编码
1349788

软骨发育不全治疗市场：按治疗类型、给药途径、分销管道和地区 - 2023 年至 2030 年的市场规模、份额、前景和机会分析

Achondroplasia Treatment Market, by Treatment Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 207 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2023 年，全球软骨发育不全治疗市场估计为 1.278 亿美元，预计在预测期内（2023-2030 年）复合年增长率为 36.5%。

报告范围 报告详细资料
基准年 2022 2023 年市场规模 美国：1.278亿美元
过去的资料 2018年至2021年 预测期间 2023-2030
预测 2023-2030 年复合年增长率： 36.50% 2030年价值预测 美国：11.26亿美元
软骨发育不全治疗市场-IMG1

软骨发育不全是一种四肢短小的侏儒症。 软骨发育不全的特征是躯干大小中等、手臂和腿部较短，尤其是上臂和大腿较短、肘部活动范围有限以及头部增大。 椎管狭窄是椎管狭窄，压迫脊髓上部，可能是软骨发育不全的严重併发症。 椎管狭窄的特征是腿部疼痛、麻木和无力，导致行走困难。 软骨发育不全是 FGFR3 基因突变引起的。 FGFR3 基因负责提供製造参与骨骼和脑组织发育和维护的蛋白质的指令。

市场动态

监管机构对软骨发育不全治疗的核准增加预计将在预测期内推动市场成长。 例如，2021年11月，全球生物技术公司BioMarin宣布，美国食品药物管理局（FDA）已确认，美国食品药物管理局（FDA）已确认线性化药物已获得加速批准。注射用VOXZOGO（vosoritide ）以指示生长加快。 此外，2021年8月，BridgeBio Pharma旗下QED Therapeutics宣布，欧盟委员会（EC）宣布生长板从2岁到青春期接近并达到最终高度，我们宣布已获得上市批准VOXZOGO（通用名：vosoritide），每日一次注射剂，用于治疗软骨发育不全。

此外，主要公司加大对软骨发育不全治疗的研究和开发预计将在预测期内推动治疗领域的成长。 例如，专门从事适体疗法的临床阶段製药公司 RIBOMIC, Inc. 于 2021 年 11 月宣布开展 RBM-007 的 1 期临床试验，用于计划治疗健康患者的软骨发育不全。我们公布了志愿者临床结果审判于2021 年5 月结束。

本次考试的主要特色

  • 本报告详细分析了全球软骨发育不全治疗市场，并介绍了以 2022 年为基准年的预测期（2023-2030 年）的市场规模和復合年增长率。
  • 它也揭示了各个细分市场的潜在收入机会，并为该市场提供了一系列有吸引力的投资建议。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景、主要参与者采取的竞争策略等的重要见解。
  • 根据公司亮点、产品组合、主要亮点、绩效和策略等参数对全球软骨发育不全治疗市场的主要参与者进行了分析。
  • 本研究涵盖的主要公司包括 BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.。
  • 本研究报告分析了全球软骨发育不全治疗市场，包括产品类型、性能、财务状况和策略等资讯。
  • 《全球软骨发育不全治疗市场报告》面向该产业的各个利害关係人，例如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 利害关係人可以透过用于分析全球软骨发育不全治疗市场的各种策略矩阵来促进决策。

目录

第一章研究目的与前提

  • 研究目的
  • 先决条件
  • 缩写

第二章市场概述

  • 报告摘要
    • 市场定义和范围
  • 执行摘要

第三章市场动态、法规与趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 市场机会
  • 影响分析
  • 近期新药发布
  • 流行病学
  • 合併、收购、联盟
  • 监管场景
  • 主要进展
  • PEST分析

第 4 章全球软骨发育不全治疗市场：COVID-19 的影响分析

  • 经济影响
  • COVID-19 的流行病学
  • 对需求和供给的影响

第 5 章软骨发育不全治疗的全球市场：依治疗类型划分，2018-2030 年

  • 沃索里□
  • 人类生长激素
  • 其他

第 6 章软骨发育不全治疗的全球市场：依给药途径划分，2018-2030 年

  • 口头
  • 注射用

第 7 章软骨发育不全治疗的全球市场：依通路划分，2018-2030 年

  • 医院药房
  • 零售药局
  • 网路药局

第 8 章软骨发育不全治疗的全球市场：按地区划分，2018-2030 年

  • 北美
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 欧洲其他地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东协
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 中东
  • 海湾合作委员会
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第九章竞争态势

  • 公司简介
    • BioMarin
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • F.Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

第 10 章

  • 参考文献
  • 调查方法
简介目录
Product Code: CMI4161

The global achondroplasia treatment market is estimated to be valued at US$ 127.8 million in 2023 and is expected to exhibit a CAGR of 36.5% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 127.8 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 36.50% 2030 Value Projection: US$ 1,126.0 Mn
Achondroplasia Treatment Market - IMG1

Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.

Market Dynamics

Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.

Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.

Key features of the study:

  • This report provides an in-depth analysis of the global achondroplasia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global Achondroplasia Treatment market based on the following parameters- Company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.

Detailed Segmentation:

  • Global Achondroplasia Treatment Market, By Treatment Type:
    • Vosoritide
    • Human Growth Hormone
    • Others
  • Global Achondroplasia Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Achondroplasia Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Achondroplasia Treatment, By Region:
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • BioMarin
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • F.Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Treatment Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Drug Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Achondroplasia Treatment Market, COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Achondroplasia Treatment Market, By Treatment Type, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Vosoritide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Human Growth Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

6. Global Achondroplasia Treatment Market, By Route of Administration, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Achondroplasia Treatment Market, By Distribution Channel, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Achondroplasia Treatment Market, By Regions, 2018 - 2030 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 - 2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • BioMarin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • RIBOMIC
    • Ascendis Pharma A/S
    • BridgeBio Pharma, Inc.
    • Pfizer Inc.
    • PhaseBio Pharmaceuticals, Inc.
    • SiSaf
    • Novo Nordisk A/S
    • F.Hoffmann-La Roche Ltd
    • LG Chem
    • Ferring B.V.
    • JCR Pharmaceuticals Co., Ltd
    • KVK TECH, INC.
    • VIVUS LLC.
    • ProLynx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Ipsen Pharma
    • Novartis AG
    • Xiamen Amoytop Biotech Co., Ltd.

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact